Clinical Trials

Prostate

Adjuvant

TORI GU-01:  A Phase II trial of adjuvant Bevacizumab (Avastin) and Erlotinib (Tarceva) in patients with high risk for early relapse following radical prostatectomy.  [UCLA]

For more information on VCHOS trials, please call Ruth Ann Begun at (805) 485-8709 ext 136 or email at rbegun@venturaoncology.com.   

For more information on  UCLA network trials, please call  Pamela Riach, RN at (805) 485-8709 ext 129 or email at priach@mednet.ucla.edu.